Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M10.0Revenue (TTM) $M12.7Net Margin (%)-136.5Altman Z-Score-4.3
Enterprise Value $M4.3EPS (TTM) $-7.2Operating Margin %-87.0Piotroski F-Score3
P/E(ttm)--Beneish M-Score-2.7Pre-tax Margin (%)-136.5Higher ROA y-yY
Price/Book0.310-y EBITDA Growth Rate %-11.0Quick Ratio2.0Cash flow > EarningsY
Price/Sales0.65-y EBITDA Growth Rate %4.3Current Ratio2.6Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-33.6Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-50.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M3.0ROIC % (ttm)-37.0Gross Margin Increase y-yN

Gurus Latest Trades with KOOL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
KOOLKen Fisher 2011-09-30 Sold Out -0.0001%$24 - $42.6
($34.49)
$ 3.33-90%Sold Out0
KOOLKen Fisher 2011-06-30 Buy $38.2 - $49.4
($43.91)
$ 3.33-92%New holding1,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

KOOL is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


KOOL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Harris KennethFormer Director/Officer 2015-11-10Sell4,043$12-72.25view
Harris KennethFormer Director/Officer 2015-11-03Sell526$12-72.25view
Harris KennethFormer Director/Officer 2015-10-29Sell432$12-72.25view
Plavan Matthew TFormer CEO 2015-09-02Sell864$13.6-75.51view
Rhein Denis MichaelDirector 2014-12-01Sell0$0-75.51view
ENGLE J MELVILLEChairman & CEO 2011-03-10Buy1,125$46-92.76view
ARTILES JORGEVP, Quality/Regulatory Affairs 2010-01-13Buy5$48.8-93.18view
ENGLE J MELVILLECEO 2009-09-25Buy1,250$45.6-92.7view
MCENANY PATRICK JDirector 2009-05-19Buy313$46.4-92.82view
ENGLE J MELVILLECEO 2009-05-12Buy1,250$44-92.43view

Quarterly/Annual Reports about KOOL:

News about KOOL:

Articles On GuruFocus.com
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 11 2011 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 04 2010 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Nov 09 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares Sep 28 2009 
THERMOGENESIS Corp. (KOOL) CEO J Melville Engle buys 100,000 Shares May 12 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) May 07 2009 
THERMOGENESIS Corp. Reports Operating Results (10-Q) Feb 05 2009 

More From Other Websites
CESCA THERAPEUTICS TO EXHIBIT AT THE 2016 INTERNATIONAL SOCIETY FOR CELLULAR THERAPY ANNUAL MEETING May 24 2016
Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting May 24 2016
CESCA THERAPEUTICS INC. Financials May 21 2016
Edited Transcript of KOOL earnings conference call or presentation 12-May-16 9:00pm GMT May 20 2016
CESCA THERAPEUTICS TO REVIEW RECENT CORPORATE MILESTONES AT THE MARCUM MICROCAP CONFERENCE May 20 2016
Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference May 20 2016
Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of... May 19 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Financial Statements and Exhibits May 18 2016
Cesca Therapeutics, Inc. :KOOL-US: Earnings Analysis: Q3, 2016 By the Numbers May 18 2016
Cesca's loss more than doubles, but its regenerative treatment shows result May 13 2016
CESCA THERAPEUTICS INC. Files SEC form 10-Q, Quarterly Report May 13 2016
CESCA THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 12 2016
Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update May 12 2016
Cesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks™ Procedures at... May 11 2016
CESCA THERAPEUTICS TO REPORT THIRD QUARTER FISCAL 2016 RESULTS ON MAY 12, 2016 May 11 2016
Cesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016 May 09 2016
Cesca Therapeutics T o Present A Poster At The 2016 Annual Meeting Of The European Society For Blood... Apr 07 2016
Cesca Therapeutics To Present A Poster At The 2016 Annual Meeting Of The European Society For Blood... Mar 31 2016
Cesca Therapeutics’ Indian Subsidiary Expands Cord Blood Banking Services To Additional Hospitals... Mar 30 2016
Cesca Therapeutics Appoints Vascular Surgery Expert Lars Norgren, M.D., Ph.D. to its Clinical... Mar 23 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)